Latest Gemtuzumab ozogamicin Stories
A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease. The results are from a major phase III Cancer Research UK-funded trial led by Cardiff University. Of the 1,115 patients who took part in the trial, 68 per cent relapsed on the new treatment within three years, compared with 76 per cent of those who had the...
NEW YORK, June 14, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials and drug intelligence, recently reviewed the results presented at the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL. A new type of targeted therapy was of particular interest to reviewer Daphna Halpern, Citeline's Director of Oncology: Antibody-Drug Conjugates (ADC's). According to Ms. Halpern, "ADC's are looking to...
(Ivanhoe Newswire) -- Researchers have discovered a way of eliminating leukemic stem cells, which could lead to new treatments that may help leukemia patients achieve complete remission. The study showed leukemic stem cells can be abolished by suppressing two proteins found in the bodies of mice.Researchers say leukemic stem cells are responsible for sustaining the disease and are most likely responsible for relapse. Eliminating these cells is believed to be the key for complete...
NEW YORK, June 21 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010. (Logo:...
SILVER SPRING, Md., June 21 /PRNewswire-USNewswire/ -- Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product's safety and the drug failed to demonstrate clinical benefit to patients enrolled in...
LIMA, Peru, Jan. 14 /PRNewswire/ -- The National Cancer Coalition (NCC) and Wyeth Pharmaceuticals (Wyeth) are pleased to announce a pilot program to assist cancer patients in Latin America with donations of Wyeth's cancer-related medicines Mylotarg(TM) (gemtuzumab ozogamicin for injection) and Neumega(TM) (oprelvekin). United States Ambassador Michael McKinley and the Peruvian Health Ministry participated in a hand-over event held at the Instituto Nacional de Enfermadades Neoplacias...
By Anonymous THERAPY In an article e-publishedon April 16 ahead of print in the International Journal of Hematology, Koenecke et al. from the Hannover Medical School (Germany) reported on radioimmunotherapy (RIT) with ^sup 188^Re-labeled antiCD66 antibody in preconditioning for allogenic stem cell transplantation in high-risk acute myeloid leukemia (AML). The study included 21 patients (14 with high-risk AML; 6 with AML after myelodysplastic syndrome; and I with advanced myelodysplastic...
